Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653986 · ClinicalTrials.gov registry record
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
A clinical trial of Migraine, sponsored by AbbVie.
- Completed
- Registry status
- 391
- Enrollment target
- 1
- Study location
NCT05653986 is a study of Migraine that has completed, run by AbbVie. The registered enrollment target is 391 participants, above the 354-participant average among 102 other Migraine trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05653986, a study of Migraine, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 391 participants
- Enrollment target
- 1
- Study location
Study Summary
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will how effective the combination use of ubrogepant and atogepant is in treating adult participants with migraine. Change in migraine activity will be assessed. Urogepant (Ubrelvy) and Atogepant (Qulipta) are approved drugs for treatment of migraine in adults in the US. Approximately 432 adult participants who are prescribed Ubrogepant and atogepant by their doctors will be enrolled in this study in the United States. Participants will receive ubrogepant oral tablets and atogepant oral tablets as prescribed by their physician. Participants will be followed for 30 days. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Conditions Studied
Study Locations (1)
New York
- Montefiore/Albert Einstein /ID# 252243 - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2022-12-18 |
| Est. Completion | 2024-08-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05653986
The ClinicalTrials.gov registry entry for NCT05653986 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 391 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 354-participant average among 102 other Migraine trials with a reported enrollment target (10% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 0 interventions.
NCT05653986 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05653986 about?
NCT05653986 is a clinical study titled "An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants". Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will how effective the combination use of ubrogepant and atogepant is in treating adult participants with migraine. Change in migraine ...
What is the current status of trial NCT05653986?
This trial is currently completed. The enrollment target is 391 participants. The study started on 2022-12-18. Estimated completion is 2024-08-05.
What conditions does trial NCT05653986 study?
This clinical trial studies the following conditions: Migraine.
Who is sponsoring clinical trial NCT05653986?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653986 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.